A Status Survey On Chemotherapy-induced Nausea And Vomiting

ObjectiveTo assess the proportion of patients who have a complete response (no emesis and nouse of rescue medications) of Chemotherapy-induced nausea and vomiting (CINV) inthe overall (0-120hours), acute (0-24hours), and delayed (25-120hours) period, todetermine the impact of CINV on daily functioning, and to evaluate the proportion ofstandard regimen, as well as to improve awareness and attention of CINV guidline forclinician.MethodsA prospective observational study was performed from January2012to June2012.Each patient filled out a patient diary for each cycle from the day beforechemotherapy and for the next5days that included the number of emetic episodes,the intensity of nausea, and QoL evaluation (functional living index-emesisquestionnaire). Results351patients undergoing moderately or highly emetogenic chemotherapy wereenrolled. The overall complete response of patients in oncology derpartment receivingsingle day chemotherapy of MEC and HEC was69.9%and64.9%. CR rate ofpatients in the ward of Thyroid and Breast surgery and the ward of Gastrointestinalsurgery was41.7%and75%, respectively. Based on the FLIE assessment,80.3%,66.7%and61.9%of patients in MEC, HEC and multiday chemotherapy in oncologydepartment reported no impact on daily life (NIDL). The proportion of NIDL in theward of Thyroid and Breast surgery and the ward of Gastrointestinal surgery was58.3%and83.3%。The use of standard regimen was67.3%and16%during acute anddelayed phases in MEC group, while it was61.5%and9.6%during acute and delayedphases in HEC group.ConclusionsCINV remains a significant problem among patients undergoing chemotherapy,especially during delayed phase and the control of nausea; the phenomenon ofguideline-inconsistent CINV prophylaxis is common; the dosage of dexamethasonemay be reduced properly; the CINV results will impact on patients attitude onsubsequent CINV; more effective prophylaxis use and more attention in clinicalpractice are necessary.